CureVac N.V. (5CV.F)

2.2780 -0.0320 (-1.39%) 市場開市。 截至 03:38PM CEST。

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

版塊: Healthcare
行業: Biotechnology
全職員工: 904

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Pierre Kemula B.Sc.	MD, CFO & Member of Management Board	548.92k	無	1975
Dr. Malte Greune Ph.D.	COO, Member of Management Board & MD	426.9k	無	1965
Dr. Ulrike Gnad-Vogt M.D., Ph.D.	Senior VP & Area Head of Oncology	350.5k	無	1973
Dr. Alexander Zehnder M.B.A., M.D.	CEO, MD & Member of Management Board	無	無	1970
Dr. Myriam Mendila M.D.	Chief Development Officer, MD & Member of the Management Board	無	無	1966
Dr. Sarah Fakih	Vice President Corporate Communications & Investor Relations	無	無	無
Mr. Marco Rau L.L.M., Ph.D.	General Counsel	無	無	無
Mr. Thorsten Schuller	Head of Corporate Communications	無	無	無
Slavica Stevanovic-Heck	Head of Human Resources	無	無	無
Dr. Patrick Baumhof	Senior Vice President of Technology	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

公司管治

截至 無 止，CureVac N.V. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。